🇪🇺 Ombitasvir-Paritaprevir-Ritonavir in European Union

EMA authorised Ombitasvir-Paritaprevir-Ritonavir on 14 January 2015

Marketing authorisation

EMA — authorised 14 January 2015

  • Application: EMEA/H/C/003839
  • Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
  • Local brand name: Viekirax
  • Indication: Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. For hepatitis C virus (HCV) genotype specific activity.
  • Status: withdrawn

Read official source →

Other Virology/Hepatology approved in European Union

Frequently asked questions

Is Ombitasvir-Paritaprevir-Ritonavir approved in European Union?

Yes. EMA authorised it on 14 January 2015.

Who is the marketing authorisation holder for Ombitasvir-Paritaprevir-Ritonavir in European Union?

AbbVie Deutschland GmbH & Co. KG holds the EU marketing authorisation.